本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
精彩内容抢先看：
结直肠癌免疫治疗持续探索不断取得新突破
抗血管生成药物三线治疗 mCRC 再添新证
免疫、靶向及新药探索为结直肠癌带来新希望
赵林 教授
北京协和医院
博士，主任医师
北京协和医院肿瘤内科 副主任
北京肿瘤防治研究会消化肿瘤专家委员会 主任委员
北京抗癌协会食管癌专业委员会 副主任委员
北京肿瘤病理精准诊断研究会 副会长
国家肿瘤专业医疗质量指控中心 副主任委员
中国抗癌协会多原发和不明原发肿瘤专委会 常委委员
北京医学会肿瘤学分会 委员
CSCO 结直肠癌、食管癌专家委员会 委员
肖像获得专家知情同意
审批码：PP-FR-CN-1374
参考文献：
[1] Chalabi M, et al. Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2. 2024 ESMO LBA24.
[2] GOOYER P D, VERSCHOOR Y, DUNGEN L V, et al. Neoadjuvant nivolumab plus Relatlimab in MMR-deficient Colon Cancer: Results of the NICHE-3 Study. 2024 ESMO. 503O.
[3] 中国临床肿瘤学会（CSCO）.《结直肠癌诊疗指南 2024》.
[4] Tougeron D,et al. Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial.2024 ESMO 502O.
[5] Ng K, et al.SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC).2024 ESMO LBA26.
[6] Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496.
[7] Dasari A,et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
[8] https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20180905101101372.html
[9] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer
[10] HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda. Retrieved June 21, 2024 from https://www.globenewswire.com/news-release/2024/06/21/2902512/0/en/HUTCHMED-Announces-European-Commission-Approval-for-FRUZAQLA-fruquintinib-Received-by-Takeda.html
[11] Garcia-Carbonero G, et al. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial.2024 ESMO 520Р.
[12] Elez Fernandez M.E, et al. Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age.2024 ESMO 526Р.
[13] Siena S, et al. Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study.2024 ESMO 505O.
[14] Tabernero J, et al. Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600Emutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI).2024 ESMO 515MO.
[15] Pietrantonio F, et al. Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/ll study.2024 ESMO 513MO.
[16] Hendifar A, et al. Phase Ib/ll study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results.2024 ESMO 575Р.
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场
✩ 本文仅供医疗卫生等专业人士参考
内容策划：季慧敏
项目审核：李淳
题图来源：丁香园设计
